Erin Davis

Erin Davis

Auto-generated profile, based on publicly available information

Erin Davis

Memorial University of Newfoundland, St. John’s, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
meshari alwashmimeshari alwashmi
meshari alwashmi
JHJohn Hawboldt
John Hawboldt
EDErin Davis
Erin Davis
MFMichael D Fetters
Michael D Fetters
Although patients express an interest in using mobile health (mHealth) interventions to manage their health and chronic conditions, many current mHealth interventions are difficult to use. Usability testing is critical for the success of novel mHealth interventions. Researchers recognize the utility of using qualitative and quantitative approaches for usability testing, but many mHealth researchers lack the awareness of integration approaches from advances in mixed methods research that can add value to mHealth technology.

1 September 2016 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
meshari alwashmimeshari alwashmi
meshari alwashmi
JHJohn Hawboldt
John Hawboldt
EDErin Davis
Erin Davis
Carlo MarraCarlo Marra
Carlo Marra
JGJM Gamble
JM Gamble
WAWaseem Abu Ashour
Waseem Abu Ashour
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

10 June 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
meshari alwashmimeshari alwashmi
meshari alwashmi
BFBeverly FitzPatrick
Beverly FitzPatrick
EDErin Davis
Erin Davis
JGJM Gamble
JM Gamble
JFJamie Farrell
Jamie Farrell
JHJohn Hawboldt
John Hawboldt
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Using a Mobile Health (mHealth) intervention, consisting of a smartphone and compatible medical device, has the potential to enhance Chronic Obstructive Pulmonary Disease (COPD) treatment outcomes while mitigating health care costs. The purpose of this study is to understand the perceptions of health care providers (HCPs) regarding the use of mHealth in COPD management. Objective: To explore the potential facilitators and barriers among HCPs regarding the use of mHealth interventions for COPD management. Methods: This is a qualitative study. Semi-structured individual interviews were conducted with 30 HCPs, including nurses, pharmacists, and physicians who work directly with COPD patients. A flexible prompts guide was used to facilitate discussions. Topics included: demographics, mHealth usage, perceptions towards challenges of mHealth adoption, factors facilitating mHealth adoption, and preferences regarding features of the mHealth intervention for COPD management. Interviews were conversational in nature and items were not asked verbatim or in the order presented. The interviews were transcribed verbatim and compared against the digital recordings to ensure the accuracy of the content. After creating a codebook for analysis, two researchers independently coded the remaining interview data using pattern coding. They discussed commonalities and differences in coding until consensus was reached. Results: A total of 30 nurses, physicians, and pharmacists participated. The main facilitators to mHealth adoption are possible health benefits for patients, ease of use, educating patients and their HCPs, credibility, and reducing the cost to the healthcare system. Alternatively, the barriers adoption are technical issues, privacy and confidentiality issues, lack of awareness, potential limited uptake from the elderly, potential limited connection between patients and HCPs, and finances. Conclusions: It is important to understand the perceptions of HCPs regarding adoption of innovative mHealth interventions for COPD management. This study identifies some potential facilitators and barriers that may inform the successful development and implementation of mHealth interventions for COPD management.

23 July 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
meshari alwashmimeshari alwashmi
meshari alwashmi
BFBeverly FitzPatrick
Beverly FitzPatrick
JFJamie Farrell
Jamie Farrell
JGJM Gamble
JM Gamble
EDErin Davis
Erin Davis
JHJohn Hawboldt
John Hawboldt
Background: Using a mobile health (mHealth) intervention consisting of a smartphone and compatible medical device has the potential to enhance chronic obstructive pulmonary disease (COPD) treatment outcomes while mitigating health care costs. Objective: This study aims to describe the demographics, use, and access to smartphones of patients with COPD. It also aims to explore and develop an understanding of potential facilitators and barriers that might influence patients using mHealth interventions for COPD management. Methods: This was an explanatory, sequential mixed methods study. Patients who attended respirology clinics completed a questionnaire on technology access and use. We conducted semistructured individual interviews with the patients. Interview topics included the following: demographics, mHealth use, perceptions toward challenges of mHealth adoption, factors facilitating mHealth adoption, and preferences regarding features of mHealth interventions for COPD management. Results: A total of 100 adults completed the survey but 22 participants were excluded because they were not diagnosed with COPD. Of these, 10 patients with COPD participated in the interview. The quantitative component revealed that many patients with COPD owned a mobile phone, but only about one-fourth of the participants (18/77, 23%) owned a smartphone. The likelihood of owning a smartphone was not associated with age, sex, marital status, or geographical location, but patients with high educational status were more likely to own a smartphone. The qualitative component found that patients with COPD, in general, had a positive attitude toward mHealth adoption for COPD management, but several facilitators and barriers were identified. The main facilitators of mHealth adoption are possible health benefits for patients, ease of use, educating patients, and credibility. Alternatively, the barriers to adoption are technical issues, lack of awareness, potential limited uptake from older adults, privacy and confidentiality issues, finances, and lack of interest in mHealth Conclusions: It is important to understand the perceptions of patients with COPD regarding the adoption of innovative mHealth interventions for COPD management. This study identifies some potential facilitators and barriers that may inform the successful development and implementation of mHealth interventions for COPD management.

17 August 2020 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
CPCaroline J. Porr
Caroline J. Porr
PRPatricia Rios
Patricia Rios
HBHarpreet S. Bajaj
Harpreet S. Bajaj
AEAoife Egan
Aoife Egan
CHCeline Huot
Celine Huot
ATAndrea C. Tricco
Andrea C. Tricco
Background: Recent surveys of Canadian cannabis users reflect increasing consumption rates, some of whom may have diabetes. However, healthcare providers have limited information resources on the effects of recreational cannabis in people with diabetes. This rapid review was commissioned by Diabetes Canada to synthesize available evidence to guide recommendations for care of people 13 years of age and older who live with diabetes. Methods: PubMed, Embase and PsycINFO databases were searched from January 2008 to January 2019. Study selection, data abstraction and quality appraisal were completed by pairs of reviewers working independently and discrepancies were resolved by a third reviewer with pilot tests completed before each stage to ensure consistency. Data collected from included studies were tabulated and summarized descriptively. Results: The search resulted in 1848 citations of which 59 publications were selected for screening, resulting in six observational studies (2 full-text articles and 4 conference abstracts) that met the pre-defined criteria for inclusion. Five studies reported higher glycated hemoglobin (HbA1c) in people with type 1 diabetes (T1D) who consumed recreational cannabis. In one study, students aged 17 to 25 years living with T1D self-reported poorer glycemic control and higher HbA1c when smoking cannabis. In one study of adults with T1D, cannabis use within the previous 12 months was associated with almost double the risk of diabetic ketoacidosis compared with no cannabis use (odds ratio [OR] 1.98; confidence interval [CI] [95% CI] 1.01–3.91). Risks for peripheral arterial occlusion and myocardial infarction were found to be higher in people with type 2 diabetes (T2D) who consumed recreational cannabis, and worse renal parameters were also reported in two separate studies of T1D and T2D. Conclusions: Recreational cannabis use may negatively impact diabetes metabolic factors and self-management behaviours in people with T1D. In people with T2D, recreational cannabis may increase risks for peripheral arterial occlusion, myocardial infarction and renal disease. However, the evidence base of this rapid review was limited to six observational studies of poor to fair methodological quality, and thus, further robust, higher quality research is required to confirm the potential impact of cannabis on diabetes. Systematic review registration: PROSPERO CRD42019122829

13 October 2016 in Trials
Verified
Journal Article
Open access
PDF file
EDErin Davis
Erin Davis
CMCarlo Marra
Carlo Marra
JGJM Gamble
JM Gamble
JFJamie Farrell
Jamie Farrell
JLJoe Lockyer
Joe Lockyer
JHJohn Hawboldt
John Hawboldt
Patients with chronic obstructive pulmonary disease (COPD) are often nonadherent with medications and have poor inhaler technique. Community pharmacists can help to improve health-related quality of life and overall outcomes in patients with COPD. We aim to measure the effectiveness of a systematic, pharmacist-driven intervention on patients with diagnosed COPD. This pragmatic, parallel-group, cluster randomized controlled trial is designed to determine the effectiveness of a multifactorial, pharmacist-led intervention on medication adherence, inhaler technique, health-related quality of life, health care resource utilization including COPD exacerbations, and use of medications. Participating pharmacies in Newfoundland and Labrador (NL), Canada will be randomly assigned to either the intervention or the control group. The intervention group will deliver an enhanced form of care that emphasizes COPD management. The control group will provide usual care and a COPD education pamphlet. Included patients will be aged 40 years or older, have a physician-confirmed diagnosis of COPD, and be able to answer questionnaires in English. The primary outcomes are the between-group difference in the change from baseline to 6 months in medication adherence using the Medication Possession Ratio (MPR) and the Morisky Medication Adherence Scale (MMAS-8). The secondary outcomes are also measured from baseline to 6 months, and include the proportion of patients with a clinically significant change in adherence, the proportion of patients defined as having “good adherence,” the mean MPR between groups, quality of life as measured by the St. George’s Respiratory Questionnaire, medication inhalation technique using a pharmacist-scored checklist, health care resource utilization and antibiotic and orally administered corticosteroid use for COPD exacerbations. Differences between groups will be analyzed at the individual patient level while controlling for clustering effect. A pharmacist-led COPD intervention has the potential to improve patient medication adherence, thus increasing quality of life, possibly decreasing pulmonary exacerbations and reducing utilization of acute health care resources. Methods and results taken from this study could be used to enhance the delivery of COPD care by community pharmacists in a real-world setting. This would serve to enhance COPD population health and quality of life. International Standard Randomized Controlled Trial Number (ISRCTN) ISRCTN78138190 , registered on 3 February 2016.